Discovery on Target
Discovery on Target Mobile Header
2013 Archived Content

Pharma’s leading targeting event delivers record attendance: 30% growth over 2012

Next Event to Take Place October 8-10, 2014 in Boston

Discovery on Target would like to thank the 800+ speakers, attendees, sponsors and exhibitors who came to Boston for this year’s annual event. The event drew a record number of attendees from 24 countries networking and discussing current and emerging ‘hot’ drug targets for the pharmaceutical industry.


Highlights of this year’s Discovery on Target include:

  • 150+ scientific presentations and 175+ speakers across 12 conference tracks and 10 short courses
  • New Tracks:
    • Targeting Epigenetic Readers
    • Antibodies Against Membrane Protein Targets
    • Targeting Histone Demethylases
    • Functional Genomics Screening Strategies
    • GPCR-Targeted Therapeutics
    • Cardio-Metabolic Drug Targets
  • Exhibit hall of 30+ companies with novel technologies and solutions
  • 40+ posters featuring cutting edge research from current and up-and-coming scientists and industry professionals
  • Poster Award Winner: Identification of Small Molecule Inhibitors for the Histone Lysine Demethylase JARID1AJoyce Sayegh; Jian Cao; Michael Norcia; Denton Hoyer; Jane S. Merkel; Qin Yan; and Molly Gale from Yale University
  • Student Fellowship Program offered to full time graduate students and Ph.D. candidates
  • New plenary keynote program – a first for Discovery on Target. Two hugely talented scientists presented critical research and innovating approaches they are making in drug discovery. The first speaker was Stuart Schreiber, Director of Chemical Biology and Founding Member, Broad Institute of Harvard and MIT and Morris Loeb Professor of Chemistry and Chemical Biology at Harvard University. Stuart talked about how advances in human biology are now accelerating patient-based drug discovery. The second keynote presenter was Paul Feldman, Senior Vice President at GlaxoSmithKline. Paul spoke about enteroendocrine drug discovery for the treatment of metabolic diseases.

Save the date!

Next year’s Discovery on Target will be held in Boston on October 8-10, 2014 in Boston

Missed the event?

Order the event proceedings. Although, we can’t make up for the networking and face-to-face discussions, we do offer conference proceedings on CD. Order the entire event proceedings now available on CD! Click here to place your order.

Also, you can also some of news by visiting live tweets that were posted from the event - #DOTBoston13.

Interested in speaking, sponsoring, or exhibiting in 2014?

We will soon begin working on the program agenda for 2014. If you are interested in speaking, please contact Cindy Crowninshield, RDN, LDN, Conference Director, at

To secure a sponsorship or exhibit package for 2014, contact Jon Stroup, Business Development Manager at

Hear what attendees have said about this year’s event!

I was very impressed by the new conference program focusing on generating and characterizing Abs to membrane protein targets. This is a great forum and I will certainly plan to attend next time around.BBC, LLC 

The Discovery on Target event is a great place to meet with thought leaders in the field and to discuss the state of the art in both formal and informal settings. There is a perfect balance of information coming from industry and academia that places everything in a mutually believable and applicable context."
Market Segment Manager, Functional Genomics, Sigma Life Science 

The Functional Genomics Screening conference was a wonderful opportunity to interact with key opinion-leaders and truly uncover unmet needs in their workflow.
Leading Technology Provider and Sponsor 

The RNAi meeting is a great place to learn about new screening technologies and to interact with screening center directors from around the world.
Brent Cochran, GBM Stem Cell Screens 

Great organization, venue, speakers, and city. Not too big, not too small, it’s just right. Wide-range of topics that will equip you for drug discovery.

I liked the speed networking session on your program that opened on your agenda. It was a creative productive use of time once we started talking with each other. It was hard to stop. You should do it again. A highly informative meeting, too.

What I love about your meetings, besides the excellent talks, is that one has a chance to really meet and talk to luminaries in the field. At a big society meeting, you usually can’t get within a 20 foot radius of them.
Bristol Myers Squibb 

This was a really great meeting. I learned a lot about an area my work is moving into, which is allosteric kinase inhibitors. Thank you for putting this together
Bristol Myers Squibb 

It was great to network with the other speakers and the audience. I thought the session was well organized, the topics were relevant, and the discussions were insightful.

Thank you very much for the very dynamic and informative meeting and the opportunity to present our work. I did enjoy both days of the conference including panel and roundtable discussions. Also, I think it was just the right balance between GPCR drug discovery and joined sessions. Thank you and looking forward to future Discovery on Target events.
The Scripps Research Institute 

The meeting was a great occasion full of tremendous opportunities to learn, interact with expertise from different areas, as well as network. I really felt that [I was] coming back home with a lot [of] gains.
Janssen Research & Development, LLC 

It was a pleasure to participate and many thanks again for giving me the opportunity. I think it was an absolutely fantastic conference, one of the highest quality that I have attended in the past several years.
Research Advisor, Computational Chemistry, Eli Lilly 

Thank you for organizing a great conference. It was very informative.
Dir., Structural Bio., Receptos 

Thanks for inviting me to participate. It was an excellent event with some good speakers, especially in the afternoon session I got to chair.
VP, Receptor Pharmacology, Array 

I enjoyed the meeting. I received enthusiastic feedback from the audiences after my talk.
Associate Professor of Medicine, Harvard Medical School 

Thanks again to your organization. Covered the landscape nicely.
CEO, Madrigal Pharmaceuticals 

I really enjoyed the conference and heard several people say the same thing. It was perceived by me and others to be a unique and timely subject matter. I felt the talks were well-prepared and on-point, and people showed a lot of good data which was great to see. Everything stayed on time and there were no lulls in activity.

It has been a valuable conference to me with a very good program, the quality of the presentations has in general been excellent. It was good to see that speakers presented novel work besides work that had been published.

Thank you for including me in the meeting on Antibodies Against Membrane Protein Targets. I was impressed with the quality of the talks and made some good contacts. The setting was excellent. I received some very good feedback on my presentation and look forward to following up with some of the people who contacted me after my talk.

Thank you for the opportunity to participate in today’s meeting. I thoroughly enjoyed both the presentation and the roundtable discussion. I thought you did a nice job generating a well rounded, relevant set of speakers. Well done. I look forward to attending this series in the future.

Many thanks to you and your associates for organizing an excellent program for the Antibodies targeting Membrane Proteins component for Discovery on Target. It was a very enjoyable event with great discussions.

Thanks for organizing another fabulous meeting. The new antibodies track seemed to work very well.
Rockefeller University 

I thought the conference was very good—well organized, a good mix of academic and industrial speakers, and the topics were very relevant. I would definitely recommend it to others interested in this area of research.
Sorrento Therapeutics 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Register Today!

Final Agenda Now Available









The exhibit hall was sold out in 2015, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2016, contact:

Jon Stroup
Sr. Business Development Manager






Next-Generation Histone Deacetylase Inhibitors

Strategies for Tackling Rare Genetic Diseases

Understanding CRISPR: Mechanisms and Applications

Autoimmunity – Small Molecule Approaches

NK Cell-Based Cancer Immunotherapy

Medical Dermatology Therapeutic R&D and Technical Innovation



Targeting Histone Methyltransferases and Demethylases

Targeting the Ubiquitin Proteasome System

Targeting the Microbiome
– Part 1

GPCR-Based Drug Discovery - Part 1

Advances in Gene Editing and Gene Silencing – Part 1

Gene Therapy Breakthroughs

Antibodies Against Membrane Protein Targets – Part 1

Targeting Cardio-Metabolic Diseases

Targeting Ocular Disorders


Targeting Epigenetic Readers and Chromatin Remodelers

Kinase Inhibitor Discovery

Targeting the Microbiome
– Part 2

GPCR-Based Drug Discovery - Part 2

Advances in Gene Editing and Gene Silencing – Part 2

Translating Cancer Genomics

Antibodies Against Membrane Protein Targets – Part 2

Metabolomics in Drug Discovery

TRAINING SEMINAR: Data Visualization


Monday, September 19
8:00 - 11:00 am

(SC1) Immunology Basics for Chemists

(SC2) Designing Peptide Therapeutics for Specific PPIs

(SC3) Phenotypic Screening and Chemical Probe Development

(SC4) Medical Dermatology Therapeutic R&D and Technical Innovation - Part 1

Monday, September 19
2:00 - 3:00 pm

(SC5) GPCR Structure-Based Drug Discovery

(SC6) RNA as a Small Molecule Drug Target

(SC7) Using IP Landscape Studies to Improve Your Confidence

(SC8) Medical Dermatology Therapeutic R&D and Technical Innovation - Part 2

Monday, September 19
3:30 - 6:30 pm

(SC9) Targeting of GPCRs with Monoclonal Antibodies

(SC10) Introduction to Targeted Covalent Inhibitors

(SC11) Contact Lens Drug Delivery Systems

(SC12) Introduction to Gene Editing

Monday, September 19
7:00 - 9:30 pm

(SC13) Convergence of Immunotherapy and Epigenetics for Cancer Treatment

Wednesday, September 21
7:00 - 9:30 pm

(SC14) Cancer Metabolism: Pathways, Targets and Clinical Updates

(SC15) Introduction to Allosteric Modulators and Biased Ligands of GPCRs

(SC16) Functional Screening Strategies Using CRISPR and RNAi

(SC17) Challenges and Opportunities in DNA Methyl Transferase (DNMT) Inhibitors as Therapeutics